Why Did Galera Therapeutics Shares Plunge To All Time Lows Today?

  • Galera Therapeutics Inc GRTX stock has plunged to all-time since its listing in November 2019 in reaction to disappointing data from the Phase 3 ROMAN trial of avasopasem manganese in severe oral mucositis (SOM) patients with locally advanced head and neck cancer (HNC) undergoing standard-of-care radiotherapy. 
  • The trial did not meet its primary endpoint of reduction in the incidence of SOM. The Company continues to analyze the results.
  • Key findings:
  • 16% relative reduction in the incidence of SOM in the avasopasem treatment group (54%) vs. placebo group (64%), the primary endpoint.
  • 56% relative reduction in the number of days of SOM in the avasopasem treatment group (8 days) vs. placebo group (18 days).
  • 27% relative reduction in the severity in the avasopasem treatment group (24%) vs. placebo.
  • Avasopasem was generally well tolerated with similar rates of adverse events in the active and placebo arms.
  • Oral mucositis is a side effect of radiation therapy characterized by severe pain, inflammation, ulceration, and bleeding of the mouth.
  • Related: Galera's Lead Candidate Shows Median OS Of 20 Months In Pancreatic Cancer Study.
  • Price Action: GRTX shares dropped 70.7% to $2.17 during the premarket session on the last check Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsShort IdeasHealth CareMoversTrading IdeasGeneralBriefsneck cancerPhase 3 Trialwhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!